113.94
+1.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rhythm Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Rhythm Pharmaceuticals is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RYTM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $189.8m and a net loss of $196.5m. At that date it held total assets of $480.2m and shareholders' equity of $139.1m.
We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. While obesity affects hundreds of millions of people worldwide, we are developing therapies for a subset of individuals who have hyperphagia, a pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, decreased energy expenditure and severe obesity due to diseases such as acquired or congenital hypothalamic obesity, Bardet-Biedl syndrome (BBS), Prader-Willi syndrome (PWS) and other diseases caused by impaired MC4R pathway signaling. The MC4R pathway is a neuro-endocrine pathway in the brain that is responsible for regulating hunger, caloric intake and energy expenditure, which consequently affect body weight. IMCIVREE, our most advanced MC4R agonist for which we hold worldwide rights, is the first-ever therapy that is marketed in the United States, European Union (EU), United Kingdom, Canada and several other countries and regions for certain rare MC4R pathway diseases, including BBS. We also are developing two earlier-stage investigational MC4R agonists, bivamelagon (formerly LB54640), an oral small molecule, and RM-718, designed for weekly subcutaneous administration.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Oct 2017
- Employees
- 414
- Website
- rhythmtx.com ↗
- Head office
- 222 BERKELEY STREET, BOSTON, MA, 02116
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. David MeekerChairman of the Board, President, Chief Executive Officer, since 2015$14.7m
- Mr. Hunter SmithChief Financial Officer, Treasurer$5.1m
- Ms. Pamela CramerChief Human Resources Officer
- Ms. Jennifer LeeExecutive Vice President, Head of North America$4.3m
- Mr. Yann MazabraudExecutive Vice President, Head of International$5.6m
- Mr. Joseph ShulmanChief Technical Officer$3.4m
- Dr. Alastair GarfieldChief Scientific Officer
- Mr. Edwards MathersLead Independent Director$659,342
- Mr. Stuart ArbuckleIndependent Director$625,675
- Dr. Camille BedrosianIndependent Director$628,175
- Ms. Jennifer GoodIndependent Director$621,842
- Mr. Christophe JeanIndependent Director$624,342
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 34
- Social
- 43
- Governance
- 19
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong product portfolio: Rhythm Pharmaceuticals Inc offers a diverse range of innovative pharmaceutical products, which positions the company for growth and resilience in the competitive market.
- Experienced management team: The company benefits from a skilled management team with extensive industry knowledge, enabling effective decision-making and strategic planning.
- Robust research and development capabilities: Rhythm Pharmaceuticals Inc invests significantly in research and development, allowing for the creation of new and improved pharmaceutical solutions to meet market demands.
Weaknesses
- Reliance on a limited number of products: The company's success is heavily dependent on a few key products, which could expose Rhythm Pharmaceuticals Inc to risks in case of product failures or declining demand.
- Vulnerability to regulatory changes: The pharmaceutical industry is subject to stringent regulations, and any changes in regulations related to drug development, approval, or pricing could impact the company's operations and profitability.
- Limited market presence: Rhythm Pharmaceuticals Inc faces competition from well-established pharmaceutical companies with larger market shares, which can pose challenges in gaining significant market share and brand recognition.
Opportunities
- Emerging markets: Expanding into emerging markets presents an opportunity for Rhythm Pharmaceuticals Inc to tap into underserved regions and potentially drive revenue growth.
- Technological advancements: The company can leverage technological advancements in drug delivery systems, precision medicine, or genetic therapies to develop innovative products and gain a competitive advantage.
- Strategic partnerships and collaborations: Collaborating with other pharmaceutical companies or academic institutions can enhance Rhythm Pharmaceuticals Inc's research capabilities and provide access to new markets or distribution channels.
Threats
- Intense competitive pressure: The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Rhythm Pharmaceuticals Inc may face aggressive pricing strategies, imitation of products, or competition from large pharmaceutical companies.
- Patent expirations: The expiration of patents on key products can open doors for generic drug manufacturers, leading to increased competition and potential revenue loss for Rhythm Pharmaceuticals Inc.
- Economic downturns: Economic recessions or instability can impact consumer spending on pharmaceutical products, potentially reducing demand and affecting the company's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.